secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2026-05-13T11:05:34+00:00
Accession:  0001493152-26-022600
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q1 2026 net loss $3.1M; revenue falls to $20.9M, raises 2026 guidance to $101-105M
--------------------------------------------------------------------------------

- Q1 2026 revenue $20.9M vs $32.9M YoY; decline driven by asset sale to Companion Spine and license revenue ceasing.
- Net loss of $3.1M vs net income of $58K in Q1 2025; non-GAAP adjusted EBITDA loss $1.6M vs +$3.0M.
- Full-year 2026 revenue guidance raised to $101-105M from $95-99M reflecting HEMOBLAST incremental revenue.
- Entered exclusive US distribution for Dilon Technologies' HEMOBLAST Bellows; hired approx. 20-person sales team.
- Reduced total indebtedness by $13.3M; cash $12.2M, availability under revolver $11.8M as of March 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/0001493152-26-022600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315226022600/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer